Re this morning's Jefferies DVAX report:
I’ve already seen a couple of posts and received 2 PM’s all trumpeting the $5 price target; unfortunately, none of these people seem to have read the release.
Jeffries is predicting a CRL on Friday. They’re then going to buy on weakness. They think the company can eventually get a limited label for vaccinating chronic kidney disease patients for Hep B, then a broad label in 2015, then be worth $5.
Not on Friday!
All that is needed to make a happy life is within yourself, in your way of thinking. -Marcus Aurelius